AFL

Aflac Inc Price

Closed
AFL
$112.88
-$0.79(-0.69%)

*Data last updated: 2026-05-02 15:49 (UTC+8)

As of 2026-05-02 15:49, Aflac Inc (AFL) is priced at $112.88, with a total market cap of $58.15B, a P/E ratio of 16.03, and a dividend yield of 2.08%. Today, the stock price fluctuated between $110.17 and $114.98. The current price is 2.45% above the day's low and 1.82% below the day's high, with a trading volume of 1.60M. Over the past 52 weeks, AFL has traded between $109.55 to $117.30, and the current price is -3.76% away from the 52-week high.

AFL Key Stats

Yesterday's Close$113.67
Market Cap$58.15B
Volume1.60M
P/E Ratio16.03
Dividend Yield (TTM)2.08%
Dividend Amount$0.61
Diluted EPS (TTM)9.03
Net Income (FY)$3.64B
Revenue (FY)$17.43B
Earnings Date2026-08-04
EPS Estimate1.84
Revenue Estimate$4.14B
Shares Outstanding511.60M
Beta (1Y)0.652
Ex-Dividend Date2026-02-18
Dividend Payment Date2026-03-02

About AFL

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. It operates through two segments, Aflac Japan and Aflac U.S. The Aflac Japan segment offers cancer, medical, nursing care income support, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan. The Aflac U.S. segment provides cancer, accident, short-term disability, critical illness, hospital indemnity, dental, vision, long-term care and disability, and term and whole life insurance products in the United States. It sells its products through sales associates, brokers, independent corporate agencies, individual agencies, and affiliated corporate agencies. The company was founded in 1955 and is based in Columbus, Georgia.
SectorFinancial Services
IndustryInsurance - Life
CEODaniel Paul Amos
HeadquartersColumbus,GA,US
Official Websitehttps://www.aflac.com
Employees (FY)12.71K
Average Revenue (1Y)$1.37M
Net Income per Employee$286.72K

Aflac Inc (AFL) FAQ

What's the stock price of Aflac Inc (AFL) today?

x
Aflac Inc (AFL) is currently trading at $112.88, with a 24h change of -0.69%. The 52-week trading range is $109.55–$117.30.

What are the 52-week high and low prices for Aflac Inc (AFL)?

x

What is the price-to-earnings (P/E) ratio of Aflac Inc (AFL)? What does it indicate?

x

What is the market cap of Aflac Inc (AFL)?

x

What is the most recent quarterly earnings per share (EPS) for Aflac Inc (AFL)?

x

Should you buy or sell Aflac Inc (AFL) now?

x

What factors can affect the stock price of Aflac Inc (AFL)?

x

How to buy Aflac Inc (AFL) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

Hot Posts About Aflac Inc (AFL)

BridgeJumper

BridgeJumper

05-01 09:06
Just realized something pretty wild about the scale of BlackRock and its leadership. So Larry Fink, the CEO, has a net worth hitting $1.1 billion according to recent figures. That alone tells you something about how massive this institution operates. What got me thinking about this was looking at his compensation structure. The guy pulls between $20-40 million annually from BlackRock, and that's just base operations. In 2022 alone, his total compensation package came to over $32.7 million—we're talking $1.5 million base salary, a $7.25 million bonus, and stock awards worth around $23.25 million. When you break down Larry Fink's net worth relative to median employee compensation, the ratio sits at 212 times. That's the AFL-CIO data for fiscal 2022. But here's where it gets interesting. As of February 2024, SEC filings show Fink owns 414,146 BlackRock shares. With the stock trading around $761.28, those holdings alone are worth north of $315 million. So his Larry Fink net worth of $1.1 billion isn't just theoretical—a huge chunk is locked into the company itself. Now think about this: BlackRock is literally the investment institution holding the most Bitcoin globally. When you consider that the CEO's personal wealth is this deeply tied to the company's performance and direction, you start wondering what that means for where Bitcoin and crypto assets might head. The concentration of wealth and influence here is genuinely something to pay attention to if you're following institutional adoption of digital assets.
0
0
0
0
TechubNews

TechubNews

04-26 22:39
Pulse Biosciences ($PLSE) announced the initial human feasibility study results for its nPulse cardiac catheter at the “Heart Rhythm 2026” conference. The most noteworthy part of this release is the procedural success rate and safety. At 6 months, 95 out of 95 cases were successful, achieving 100%; at 12 months, 51 out of 53 cases were successful, for a success rate of 96%. The company said that this study is of great significance as early clinical data for the treatment of atrial fibrillation (AF). The 1-year Kaplan-Meier analysis showed that the proportion of patients free from atrial fibrillation (AF), atrial flutter (AFL), and atrial tachycardia (AT) was 90%. Serious adverse events (SAE) occurred in 3 out of a total of 177 cases, for an incidence rate of 1.7%. Procedural efficiency metrics were also relatively favorable. The average device dwell time within the left atrium was 18.6±13.0 minutes, and the total procedure time was 60.2±27.7 minutes. Fluoroscopy time was 9.4±5.9 minutes, and the average number of energy applications to achieve pulmonary vein isolation (PVI) was 12.3±2.6 times. In conventional atrial fibrillation procedures, reductions in procedure time and fluoroscopy time can affect healthcare provider fatigue, patient burden, and hospital operational efficiency; therefore, these figures are sufficient to draw market attention. The result has been interpreted as an early indicator of whether Pulse Biosciences can demonstrate its technological competitiveness in the field of cardiac electrophysiology. Since it is still in the early feasibility study stage, larger-scale follow-up clinical trials and long-term follow-up data are needed. However, based solely on the data that has been published, both the “success rate” and “safety” meet expectations. If subsequent clinical trials achieve similar results, the company’s presence in the atrial fibrillation treatment device market could be strengthened. TP AI Notice: This article is summarized based on the TokenPost.ai language model. Key textual content may be omitted or may not align with actual facts.
0
0
0
0